Johnson & Johnson MedTech partners with Pacira BioSciences to promote ZILRETTA for knee osteoarthritis pain relief. The collaboration includes professional education to raise awareness of non-surgical treatment options for OA. Over 30 million U.S. adults suffer from OA, with knee OA causing significant pain and mobility issues. ZILRETTA, approved by the FDA in 2017, offers extended pain relief lasting up to 12-16 weeks. Johnson & Johnson MedTech aims to improve patient access to early pain relief solutions and strengthen their Early Intervention portfolio. JNJ stock is currently trading at $166.98 on the NYSE.

Read more at Nasdaq: Johnson & Johnson MedTech, Pacira BioSciences Partner To Promote ZILRETTA For Knee OA Pain